Literature DB >> 28662750

Viral Vector Biosafety in Laboratory Animal Research.

Dalis E Collins1, Jon D Reuter2, Howard G Rush3, Jason S Villano4.   

Abstract

Viral vector research presents unique occupational health and safety challenges to institutions due to the rapid development of both in vivo and in vitro gene-editing technologies. Risks to human and animal health make it incumbent on institutions to appropriately evaluate viral vector usage in research on the basis of available information and governmental regulations and guidelines. Here we review the factors related to risk assessment regarding viral vector usage in animals and the relevant regulatory documents associated with this research, and we highlight the most commonly used viral vectors in research today. This review is particularly focused on the background, use in research and associated health and environmental risks related to adenoviral, adeno-associated viral, lentiviral, and herpesviral vectors.

Entities:  

Mesh：

Year:  2017        PMID： 28662750      PMCID： PMC5482513     

Source DB:  PubMed          Journal:  Comp Med        ISSN： 1532-0820            Impact factor:   0.982


  50 in total

1.  Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model.

Authors:  C Meyers; M Mane; N Kokorina; S Alam; P L Hermonat
Journal:  Virology       Date:  2000-07-05       Impact factor: 3.616

Review 2.  Risk assessment of the use of autonomous parvovirus-based vectors.

Authors:  Francis Dupont
Journal:  Curr Gene Ther       Date:  2003-12       Impact factor: 4.391

Review 3.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

4.  Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010.

Authors:  Heather Bradley; Lauri E Markowitz; Theda Gibson; Geraldine M McQuillan
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

Review 5.  Biosafety features of lentiviral vectors.

Authors:  Axel Schambach; Daniela Zychlinski; Birgitta Ehrnstroem; Christopher Baum
Journal:  Hum Gene Ther       Date:  2013-02       Impact factor: 5.695

6.  Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1.

Authors:  Q Wang; J Guo; W Jia
Journal:  Gene Ther       Date:  1997-12       Impact factor: 5.250

7.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Authors:  Marina Cavazzana-Calvo; Emmanuel Payen; Olivier Negre; Gary Wang; Kathleen Hehir; Floriane Fusil; Julian Down; Maria Denaro; Troy Brady; Karen Westerman; Resy Cavallesco; Beatrix Gillet-Legrand; Laure Caccavelli; Riccardo Sgarra; Leila Maouche-Chrétien; Françoise Bernaudin; Robert Girot; Ronald Dorazio; Geert-Jan Mulder; Axel Polack; Arthur Bank; Jean Soulier; Jérôme Larghero; Nabil Kabbara; Bruno Dalle; Bernard Gourmel; Gérard Socie; Stany Chrétien; Nathalie Cartier; Patrick Aubourg; Alain Fischer; Kenneth Cornetta; Frédéric Galacteros; Yves Beuzard; Eliane Gluckman; Frederick Bushman; Salima Hacein-Bey-Abina; Philippe Leboulch
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

8.  Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Authors:  Danilo R Casimiro; Ling Chen; Tong-Ming Fu; Robert K Evans; Michael J Caulfield; Mary-Ellen Davies; Aimin Tang; Minchun Chen; Lingyi Huang; Virginia Harris; Daniel C Freed; Keith A Wilson; Sheri Dubey; De-Min Zhu; Denise Nawrocki; Henryk Mach; Robert Troutman; Lynne Isopi; Donna Williams; William Hurni; Zheng Xu; Jeffrey G Smith; Su Wang; Xu Liu; Liming Guan; Romnie Long; Wendy Trigona; Gwendolyn J Heidecker; Helen C Perry; Natasha Persaud; Timothy J Toner; Qin Su; Xiaoping Liang; Rima Youil; Michael Chastain; Andrew J Bett; David B Volkin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 9.  Advances and future challenges in adenoviral vector pharmacology and targeting.

Authors:  Reeti Khare; Christopher Y Chen; Eric A Weaver; Michael A Barry
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

Review 10.  General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.

Authors:  Aline Baldo; Eric van den Akker; Hans E Bergmans; Filip Lim; Katia Pauwels
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391
View more
  12 in total

1.  Special Issue: Infectious Disease Research: Animal Models and Risk Management.

Authors:  Jason S Villano; Bryan E Ogden
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

2.  Optimization and Characterization of Calcium Phosphate Transfection in Mesenchymal Stem Cells.

Authors:  Chi-Wen Lo; Tzuhua Lin; Masaya Ueno; Monica Romero-Lopez; Masahiro Maruyama; Yusuke Kohno; Claire Rhee; Zhenyu Yao; Magdiel Pérez-Cruz; Everett Meyer; Stuart B Goodman
Journal:  Tissue Eng Part C Methods       Date:  2019-09       Impact factor: 3.056

Review 3.  A neuroscientist's guide to transgenic mice and other genetic tools.

Authors:  Shaghayegh Navabpour; Janine L Kwapis; Timothy J Jarome
Journal:  Neurosci Biobehav Rev       Date:  2019-12-13       Impact factor: 8.989

4.  Atherosclerosis Induced by Adeno-Associated Virus Encoding Gain-of-Function PCSK9.

Authors:  Martin Mæng Bjørklund; Juan A Bernal; Jacob F Bentzon
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges.

Authors:  Sumit Ghosh; Alex M Brown; Chris Jenkins; Katie Campbell
Journal:  Appl Biosaf       Date:  2020-03-01

6.  Treatment of Rheumatoid Arthritis with Gene Therapy Applications: Biosafety and Bioethical Considerations.

Authors:  Zinovia Tsitrouli; Maria-Anna Akritidou; Savvas Genitsaris; Gijsbert van Willigen
Journal:  BioTech (Basel)       Date:  2021-06-23

7.  Highly efficient siRNA transfection in macrophages using apoptotic body-mimic Ca-PS lipopolyplex.

Authors:  Yueyang Lai; Xuebo Xu; Zhenyu Zhu; Zichun Hua
Journal:  Int J Nanomedicine       Date:  2018-10-24

Review 8.  Macrophage reprogramming for therapy.

Authors:  Valentina M T Bart; Robert J Pickering; Philip R Taylor; Natacha Ipseiz
Journal:  Immunology       Date:  2021-01-25       Impact factor: 7.215

9.  In Vivo Expression of Reprogramming Factor OCT4 Ameliorates Myelination Deficits and Induces Striatal Neuroprotection in Huntington's Disease.

Authors:  Ji-Hea Yu; Bae-Geun Nam; Min-Gi Kim; Soonil Pyo; Jung-Hwa Seo; Sung-Rae Cho
Journal:  Genes (Basel)       Date:  2021-05-10       Impact factor: 4.096

Review 10.  A Short History of Skin Grafting in Burns: From the Gold Standard of Autologous Skin Grafting to the Possibilities of Allogeneic Skin Grafting with Immunomodulatory Approaches.

Authors:  Frederik Schlottmann; Vesna Bucan; Peter M Vogt; Nicco Krezdorn
Journal:  Medicina (Kaunas)       Date:  2021-03-02       Impact factor: 2.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.